vTv Therapeutics

[Ca$hmandt]

VTVT -78%

vTv Therapeutics Crashes on Alzheimer's Drug Study Failure

Shares of vTv Therapeutics, Inc. VTVT plummeted significantly after the company announced dismal results from the part A of the phase III trial, STEADFAST, on pipeline candidate, azeliragon.

vTv Therapeutics’ stock has plunged 50.6% in the last six months as against the industry’s decline of 18.9%.

The candidate was being evaluated in patients suffering from Alzheimer’s disease. The results showed that the candidate did not meet co-primary efficacy endpoint as patients taking azeliragon versus placebo did not improve in cognitive or functional outcomes as measured by the

Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and the Clinical Dementia [WIKI]Rating[/WIKI] Scale Sum of Boxes (CDR-sb).

...



https://finance.yahoo.com/news/vtv-t...141502023.html

[Ca$hmandt]

AW: vTv Therapeutics

Stifel Sees Challenging Road Ahead For vTv Therapeutics After Failed Alzheimer's Trial

...

The Analyst

Stifel analyst Alex Schwartz downgraded vTv Therapeutics from Buy to Hold and lowered the price target from $12 to $1.

The Thesis

Following the negative trial results, vTv Therapeutics decided to discontinue the STEADFAST Part B trial, which was due to produce final data in early 2019, Schwartz said in a Monday evening note.

If the Part A group responded to data, the company intends to factor this signal into its prespecified analysis and examine Part B data, the analyst said. This data is likely in the second quarter, the analyst said, citing the company.

Stifel adjusted its forecast for the probability of success for azeliragon from 50 percent to zero. Yet Schwartz said he sees value in the company's two underlying diabetes assets, each of which possesses positive Phase 2 data.

"However, given vTv's cash on hand, extended search to find partners for the programs and length/costs to conduct Phase III trials, we see a challenging road ahead for the company."

Stifel pushed out its projection for the launch of vTv's diabetes assets to 2024.

Schwartz identified the following as catalysts for the company:

Azeliragon Phase III Part B data: Q2 2018
TPP399 T1D Phase II data: year-end 2018
TPP273 T2D Phase II data: 2019

https://finance.yahoo.com/news/stife...133627525.html

[Ca$hmandt]

AW: vTv Therapeutics

VTVT heute 130% im plus, nach gestern dann mehr als vervierfacht...


vTv Therapeutics Inc. shares were up nearly 159% yesterday on about 21 million shares traded despite any news from the company nor catalyst to explain the jump. It was roughly two months ago that the biotech company reported its second quarter results. The company reported loss of $0.29 per share for the quarter, which trailed behind the consensus estimates of loss per share of $0.25 by $0.04. vTv Therapeutics reported revenue of $2.47 million, while analysts had expected revenue of $2.46 million. It was revealed at the end of last month that major shareholder Ronald O. Perelman had acquired 1,879,699 shares of vTv Therapeutics stock in a transaction on Thursday, September 6th. The company discovers, develops, and sells orally administered small molecule drug candidates worldwide and has a drug candidate called azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation end products, which is in Phase III clinical trials for the treatment of Alzheimer's disease.


...

https://finviz.com/quote.ashx?t=VTVT